What is new with inhibition of PCSK9?

Christie M. Ballantyne, MD Center for Cardiometabolic Disease Prevention Baylor College of Medicine Houston, Texas



Christie M. Ballantyne, MD Financial Disclosure


- **Grant/Research Support:** Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, NIH, AHA, ADA (all paid to institution, not individual)
- Consultant: Abbott Diagnostic, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Boehringer Ingelheim, Corvidia, Denka Seiken, Esperion, Gilead, Janssen, Matinas BioPharma Inc, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, Sanofi-Synthelabo




Current Therapies to Inhibit PCSK9: Monoclonal Antibodies


- Alirocumab and evolocumab initially approved in 2015
- Both lower LDL-C approximately 60%
- Given as injections either every 2 weeks or monthly
- Each agent with a large outcome trials in high-risk patients with significant reduction in MACE of approximately 15%, both relatively short-term studies








1. Delivered to hepatocytes GalNAc / ASPGR



1. Delivered to hepatocytes GalNAc / ASPGR


2. Guide strand delivers to RISC





 Delivered to hepatocytes GalNAc / ASPGR
 Guide strand delivers to RISC
 RISC-siRNA cleaves PCSK9 mRNA degraded





 Delivered to hepatocytes GalNAc / ASPGR
 Guide strand delivers to RISC
 RISC-siRNA cleaves PCSK9 mRNA degraded
 Increased LDLR density

dec circulating LDL

Design of ORION-9, -10, -11 studies

Patients^{1,2}

HeFH, ASCVD, and / or risk-equivalent patients

Age \geq 18 years


High-intensity statin

LDL-C

>70 mg/dL, or

>100 mg/dL (risk equivalent, HeFH)

18-month duration^{1,2}



1. Raal FJ et al. N Engl J Med 2020;382(16):1520-30; 2. Ray KK et al. N Engl J Med 2020;382(16):1507-19



Entry criteria

ORION-91	ORION-10 ²	ORION-112
 HeFH^a Stable on a low-fat diet LDL-C ≥100 mg/dL 	 ASCVD (CHD, CVD, PAD) LDL-C ≥70 mg/dL 	 ASCVD (CHD, CVD, PAD) ASCVD risk equivalents Type 2 diabetes 10-year risk ≥20% HeFH^a LDL-C ≥70 mg/dL
Maximally tolerated stati	n therapy (or documented intolera	nce), with or without ezetimibe
D, cardiovascular disease; CHD, chronic heart diseas	se; HeFH, heterozygous familial hypercholesterolemia criteria	r; PAD, peripheral arterial disease

1. Raal FJ et al. N Engl J Med 2020;382(16):1520-30; 2. Ray KK et al. N Engl J Med 2020;382(16):1507-19



Common end points of ORION-9, -10, -11 studies

Primary end point^{1,2}

- Percentage change in LDL-C from baseline to Day 510
- Time-adjusted percentage change in LDL-C from baseline between Day 90 and Day 540. This is the average percentage change in LDL-C from baseline over the period between Day 90 and Day 540

Key secondary end points^{1,2}

- Absolute change in LDL-C from baseline to Day 510
- Time-adjusted absolute change in LDL-C from baseline between Day 90 and Day 540
- Percentage change from baseline to Day 510 in PCSK9, total cholesterol, ApoB, and


non-HDL-C



HDL-C, high-density lipoprotein cholesterol

1. Raal FJ et al. N Engl J Med 2020;382(16):1520-30; 2. Ray KK et al. N Engl J Med 2020;382(16):1507-19

ORION-10: Patient disposition High proportion of patients completed the study



Safety population comprises any subject given any study medication



ORION-10: Patients Representative high risk cohort balanced by randomization

Patient characteristic	Placebo	Inclisiran
ITT population ¹	N = 780	N = 781
Age median (range) - years	66 (39-89)	67 (35-90)
Male gender	548 (70%)	535 (69%)
Diabetes	331 (42%)	371 (48%)
Heterozygous familial hypercholesterolemia	69 (9%)	68 (9%)
Lipid management treatment	730 (94%)	748 (96%)
Statins	692 (89%)	701 (90%)
Of which high intensity statins given	546 (79%)	538 (77%)
Ezetimibe use	74 (9%)	80 (10%)
Baseline LDL-C mg/dL (SD)	105 (37)	105 (40)

1. All patients who were randomized. analyzed according to randomization 2. SD is standard deviation

ORION-10: Efficacy Highly significant lowering of LDL-C relative to placebo



Treatment group	N (ITT)	Γ) Percent change LDL-C				
		Mean at day 510		Time-ave day 90 -		
		Observed	Imputed ¹	Observed	Imputed ²	
Placebo	780	+ 1	+ 1	+ 3	+ 3	
Inclisiran	781	- 56	- 51	- 53	- 51	
Difference (1 ^o er	ndpoint)	- 58	- 52	- 56	- 54	
P-value		<0.0	<0.00001		0001	
1 A wash-out model was used to account	for missing data					

1. A wash-out model was used to account for missing data

2. A pattern mixed model was used to account for missing data

ORION-10: Safety and tolerability Injection site AEs infrequent, mostly mild and transient



Injection site TEAEs Safety population ¹	Placebo N = 778		Inclisiran N = 781		Δ	
Protocol-defined event	7	(0.9%)	20	(2.6%)	1.7%	
(Reaction, erythema, rash, pruritus, hypersensitivity)						
Mild	7	(0.9%)	13	(1.7%)	0.8%	
Moderate	0		7	(0.8%)	0.8%	
Severe	0		0			
Persistent	0		0			
Injection site pain						
Vial + syringe (cycle 1+2)	3	(0.4%)	18	(2.1%)	1.7%	
Pre-filled syringe (cycle 3+4)	1	(0.1%)	7	(1.0%)	0.9%	

1. Safety population includes all patients who received at least 1 dose of study medication

ORION-10: Safety and tolerability No evidence of liver, kidney, muscle or platelet toxicity



Laboratory tests Safety population ^{1,2}			Placebo N = 778		Inclisiran N = 781	
iver function	ALT >3x ULN	2	(0.3%)	2	(0.3%)	
	AST >3x ULN	5	(0.6%)	4	(0.5%)	
	ALP >2x ULN	3	(0.4%)	5	(0.6%)	
	Bilirubin >2x ULN ³	3	(0.4%)	4	(0.5%)	
Kidney function	Creatinine >2 mg/dL	30	(3.9%)	30	(3.9%)	
luscle	CK >5x ULN	8	(1.0%)	10	(1.3%)	
	CK >10x ULN	2	(0.3%)	1	(0.1%)	
lematology	Platelet count <75x10 ⁹ /L	0		1	(0.1%)	
0,	Platelet count <75x10 ⁹ /L ts who received at least 1 dose of study medication		be counted in more than	1 n one category		

1. Safety population includes all patients who received at least 1 dose of study medication
 2. Patients may be counted in more than one cate
 3. No cases met Hy's Law
 Ray KK et al. N Engl I

ORION-10: Safety and tolerability No difference in serious adverse events




Serious treatment emergent adverse events Safety population ^{1,2}	Placebo N = 778		N = 781	
Patients with at least one serious TEAE		(26.3%)	175	(22.4%)
All cause death	11	(1.4%)	12	(1.5%)
Cardiovascular	5	(0.6%)	7	(0.9%)
Cancer	3	(0.4%)	1	(0.1%)
New, worsening or recurrent malignancy	26	(3.3%)	26	(3.3%)
TEAEs leading to drug discontinuation	17	(2.2%)	19	(2.4%)

1. Safety population includes all patients who received at least 1 dose of study medication 2. Patients may be counted in more than one category

ORION-11: Efficacy

Durable, potent and consistent effect over 18 months Percent change in LDL-C over time – observed values ITT patients



P-value for placebo – inclisiran companson at each time point <0.000

AMERICAN COLLEGE of

CARDIOLOGY

1. All 95% confidence intervals are less than $\pm 2\%$ and therefore are not visible outside data points

ORION-11: Safety and tolerability

No difference in serious adverse events


Safety population ^{1,2}	Placebo N=804		Inclisiran N=811	
Patients with at least one serious TEAE	181	(22.5%)	181	(22.3%)
All cause death	15	(1.9%)	14	(1.7%)
Cardiovascular	10	(1.2%)	9	(1.1%)
Cancer	3	(0.4%)	3	(0.4%)
New, worsening or recurrent malignancy	20	(2.5%)	16	(2.0%)

1. Safety population includes all patients who received at least 1 dose of study medication

2. Patients may be counted in more than one category







- Inclisiran emerged from Phase 2 with a "one size fits all" dosing regimen:
 - 300 mg SC dose on Day 1, 90, then every 180 days
 - Applicable to all patient populations and subgroups
- Consistent and durable efficacy
- No safety signals observed to date in a broad range of patient groups
- More than 3500 patients followed up to 450 days to date and more than 3000 patient-years of exposure to inclisiran across the ORION Program
- Large outcomes trial ongoing



ADHERENCE: The greatest challenge in prevention treating asymptomatic conditions such as lipids

Could inclisiran improve adherence and lead to a disruptive technology that changes the way preventive cardiology is practiced?